Startseite Kongressberichte & Archiv ESMO 2017 Congress Late breaking news LBA Press Conference: Melanoma cancer

Papers presented

Presenting Author - Jeffrey Weber: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238)

MORE INFO
ORIGINAL ARTICLE
J. Weber and Others
 
Also of Interest but not presented at the press conference:

 

Presenting Author - Axel Hauschild: COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma

MORE INFO
ORIGINAL ARTICLE
G.V. Long and Others
Comments 

 

Presenting Author - Karl Lewis: BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence